BeiGene price target raised to $350 from $348 at Guggenheim

Guggenheim analyst Michael Schmidt raised the firm’s price target on BeiGene (ONC) to $350 from $348 and keeps a Buy rating on the shares. The firm, which is updating its model to reflect Q1 results, maintains its “positive conviction” on what it identifies as its top Midcap Biotech stock pick.

Protect Your Portfolio Against Market Uncertainty

• Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
• Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.